Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.

Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Lilly Goldberg ’28 is a first-year pitcher on the Swarthmore softball team. The Pittsford native had a strong performance on ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

Lower levels of "bad" LDL cholesterol could mean a lower risk of dementia and Alzheimer's disease, a new study says.

China continues to boost pharmaceutical innovation through regulatory reforms and as a result, "the pace of new drug ...

Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

The results suggested that plasma MTBR-tau243 could help estimate the tauopathy load in Alzheimer's disease, improving ...

The death of former England footballer Trevor Whymark may have been linked to heading the ball during his professional career ...